Not all our readers are eligiable for RNA vaccines which are commonly used in the West. In the UK we have been stuck with the AZ vaccine which America didnt want. In other parts of the World people are reliant on Chinese technology and there they have gone on the standard route of taking the virus, inactivating it. Whilst this is different in that you can make responses to spike and nucleocapsif and other viral proteins rather than just spike protein as used in the RNA and adenoviral vaccines. This may have some benefits, but just like RNA and then adenoviral vectors where CD20 and fingolimod limit COVID-19 responsiveness. Here we see that sinovac is no better.
As you can see the scale goes 1, 2 3 1=10, 2=100 and 3 =1000 and so shows the increase in antibodies in not great generally with RNA vaccines the increase is 3 = 1,000 to 4 = 10,000
Etemadifar, Masoud and Sedaghat, Nahad and Nouri, Hosein and Lotfi, Noushin and Chitsaz, Ahmad and Khorvash, Reza and Zolfaghari, Hamed and Ghasemi Movaghar, Alireza and Pourabbas, Mohammad and Salari, Mehri, SARS-CoV-2 Serology Among People with Multiple Sclerosis on Disease-Modifying Therapies after BBIBP-CorV (Sinopharm) Inactivated Virus Vaccination: Same Story, Different Vaccine (October 14, 2021). SSRN: http://dx.doi.org/10.2139/ssrn.3942531
Background: Various studies indicated blunted humoral responses to COVID-19 mRNA and viral vector vaccines among people with multiple sclerosis (pwMS) on sphingosine 1-phosphate receptor (S1PR) modulators and anti-CD20 therapies (aCD20); however, no study was found assessing SARS-CoV-2 serology after inactivated virus vaccination.
Objective: To provide evidence regarding humoral response to COVID-19 inactivated virus vaccination among pwMS on disease-modifying therapies (DMTs).
Methods: A cohort study was carried out in Isfahan, Iran, enrolling DMT-exposed pwMS and unexposed (UX) healthy participants. Post-vaccination anti-SARS-CoV-2 Spike IgG serology testing was carried out among the participants and compared between participants based on their DMT exposure, using proper statistical tests. A multivariable logistic regression model was used to control for confounding. Association between the second vaccine dose-to-phlebotomy (vac2phleb) and the humoral response was investigated in each DMT-exposed cohort, using linear regression. Among the aCD20 cohort, the association of the last aCD20 infusion-to-first vaccine dose period with serostatus was investigated using an unpaired t-test.
Results: After enrolling 358 participants (144 pwMS and 214 healthy), blunted humoral responses were only observed in fingolimod (Log10 mean diff. [SE]: 0.72 [0.18], P = 0.001) and aCD20 (Log10 mean diff. [SE]: 0.75 [0.15], P < 0.001) cohorts compared to the UX cohort. Multivariable analysis confirmed the results. The study did not achieve enough statistical power to detect a significant association between the vac2phleb period and humoral responses. The last aCD20 infusion to first vaccination dose period was longer in the seroconverted pwMS on aCD20 (mean diff. [SE]: 8.43 weeks [2.57], P = 0.005).
Conclusion: The results of this study mirrored the results of previous studies among mRNA- or viral vector-vaccinated pwMS on DMTs. Therefore, it can be concluded that mode of action contributes less than timing, to the efficiency of vaccination strategies among pwMS on DMTs – especially the ones on S1PR modulators and aCD20. Meanwhile, the mentioned pwMS should be advised to receive early boosters and remain vigilant until further data becomes available and more efficient vaccination strategies are crafted.
If you want to compare antibody response of inactivated vrial vaccine versus BNT162b2 (Pfizer)You can look here
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong Mok, C. K. P., Hui, D. S.10.1101/2021.10.28.21265635 — Posted: 2021-10-30
COI Multiple but non relevant
General Disclaimer: Please note that the opinions expressed here are those of the author and do not necessarily reflect the positions of the Barts and The London School of Medicine and Dentistry nor Barts Health NHS Trust and are not meant to be interpreted as personal clinical advice.